No abstract available.
Diagnosis* ; HIV Infections* ; HIV*

HIV ; HIV Infections/diagnosis* ; Humans

A retrospective study on 11 adult patients with HIV/AIDS in the Institute of Clinical Medicine and Tropical Disease during 1998 - 2000 has shown that average ages of patients was 26.486.68, patients with ages of 16-30 accounted for highest rate (72.5%), male patients accounted for 94.6%. HIV transmission among drug addicts was highest rate (62.2%). Rate of unemployment patients was 47.7%. The average duration of treatment within 15 days found in 73.9% of patients. The clinical feature included fever (65.8%), big nodules, cough and breathing difficulty (42.3%), weight loss (30.6%), skin and mucosal lesion (27%), diarrhea (25.2%), hepatomegaly (20.7%), throat fungus (19.8%), splenomegaly (10.8%), headache (10.8%), the opportunistic infections such as herpes zoster, dermatitis, tuberculosis.
Opportunistic Infections ; HIV ; Acquired Immunodeficiency Syndrome ; diagnosis

Acute human immunodeficiency virus (HIV) infection is a transient symptomatic illness associated with high-titer HIV replication and an expansive immunologic response to the invading pathogen. The diagnosis of acute HIV infection is difficult because the symptoms are those of common illnesses and HIV antibodies are usually not detected during the early phase of infection. An accurate early diagnosis is important because of the potential clinical benefit of early antiretroviral therapy, and to prevent the spread of infection. We report a case of acute HIV infection presenting as an acute febrile illness. We started treatment with highly active antiretroviral therapy (HAART) and the patient is now well with no other complications
Acquired Immunodeficiency Syndrome ; Antiretroviral Therapy, Highly Active ; Early Diagnosis ; HIV ; HIV Antibodies ; HIV Infections ; Humans

Acute human immunodeficiency virus (HIV) syndrome develops in 40 to 90% of new HIV-1 infections. In Korea, recent increases in HIV-1 infection rates suggest that the number of patients experiencing acute HIV syndrome will also increase. Furthermore, it has been reported that aseptic meningitis occurs in 24% of patients with acute HIV syndrome. The inclusion of acute HIV syndrome in the differential diagnosis of aseptic meningitis is crucial; however, few reports of acute HIV syndrome presenting as aseptic meningitis in Korea exist. Here we report a case of aseptic meningitis in a patient who received early antiretroviral therapy after a diagnosis of acute HIV syndrome.
Diagnosis, Differential ; HIV ; HIV Infections ; HIV-1 ; Humans ; Korea ; Meningitis ; Meningitis, Aseptic

Acute human immunodeficiency virus (HIV) syndrome develops in 40 to 90% of new HIV-1 infections. In Korea, recent increases in HIV-1 infection rates suggest that the number of patients experiencing acute HIV syndrome will also increase. Furthermore, it has been reported that aseptic meningitis occurs in 24% of patients with acute HIV syndrome. The inclusion of acute HIV syndrome in the differential diagnosis of aseptic meningitis is crucial; however, few reports of acute HIV syndrome presenting as aseptic meningitis in Korea exist. Here we report a case of aseptic meningitis in a patient who received early antiretroviral therapy after a diagnosis of acute HIV syndrome.
Diagnosis, Differential ; HIV ; HIV Infections ; HIV-1 ; Humans ; Korea ; Meningitis ; Meningitis, Aseptic

The persistence of the HIV-1 reservoir is still the main obstacle to the cure of HIV. In clinical research, reliable biomarkers are needed to label it. HIV-1 DNA can be continuously detected in the HIV-1 reservoir. It has significant application value in diagnosing HIV-1 infection, the timing of antiretroviral therapy, the prediction of virus rebound, and monitoring treatment effects. The detection technology based on polymerase chain reaction (PCR) is the most commonly used HIV-1 DNA detection method in clinical practice. The continuous innovation and advancement of technology can accurately detect the total, integrated, and unintegrated HIV-1 DNA in infected cells using qualitative or quantitative methods. Different forms of HIV-1 DNA in infected cells have been increasingly reported as biomarkers in HIV infection monitoring and AIDS treatment-related research. This article reviews the progress of HIV-1 DNA.
Humans ; HIV-1/genetics* ; HIV Infections/diagnosis* ; DNA ; Polymerase Chain Reaction ; HIV Seropositivity

Objective To propose the blood detection strategies for human immunodeficiency virus (HIV) among blood donors, and provide reference for the detection, early diagnosis and transmission blocking of HIV. Methods A total of 117 987 blood samples from blood donors were screened using the third- and fourth-generation ELISA HIV detection reagents. Western blot analysis was used to verify the reactive results of the third-generation reagent alone, or both the third-generation and fourth-generation reagents. HIV nucleic acid test was carried out for those with negative test results of the third- and fourth-generation reagents. For those with positive results of the fourth-generation reagent only, nucleic acid test followed by a confirmatory test by Western blot analysis was carried out. Results 117 987 blood samples from blood donors were tested by different reagents. Among them, 55 were tested positive by both the third- and fourth-generation HIV detection reagents at the same time, accounting for 0.047% and 54 cases were confirmed HIV-positive by Western blot analysis, and 1 case was indeterminate, then turned positive during follow-up testing. 26 cases were positive by the third-generation reagent test alone, among which 24 cases were negative and 2 were indeterminate by Western blot analysis. The band types were p24 and gp160 respectively detected by Western blot analysis, and were confirmed to be HIV negative in follow-up testing. 31 cases were positive by the fourth-generation HIV reagent alone, among which 29 were negative by nucleic acid test, and 2 were positive according to the nucleic acid test.Western blot analysis was used to verify that the two cases were negative. However, after 2~4 weeks, the results turned positive when the blood sample was retested by Western blot analysis during the follow-up of these two cases. All the specimens that were tested negative by both the third- and fourth-generation HIV reagents were validated negative by HIV nucleic acid test. Conclusion A combined strategy with both third- and fourth-generation HIV detection reagents can play a complementary role in blood screening among blood donors. The application of complementary tests, such as nucleic acid test and Western blot analysis, can further improve the safety of blood supply, thus contributing to the early diagnosis, prevention, transmission and treatment of blood donors potentially infected by HIV.
Humans ; HIV Infections/diagnosis* ; HIV Antibodies ; Blood Donors ; HIV-1 ; Blotting, Western ; Nucleic Acids

Generally, laboratory testing for human immunodeficiency virus (HIV) is done for three reasons: for individual diagnosis and clinical management; to ensure the safety of blood or tissue products; and for public health surveillance. Many HIV-infected patients are unaware of their infections. The early diagnosis of infection is critical for medical and public health reasons. Its diagnosis is a two-step process that requires the sequential use of a highly sensitive screening test, followed by a highly specific confirmatory test. HIV-testing technology continues to evolve, with various tests currently available. This article reviews the current status of and recent advances in HIV testing.
Diagnosis ; Early Diagnosis ; HIV Infections* ; HIV* ; Humans ; Mass Screening ; Public Health ; Public Health Surveillance

OBJECTIVEThis study was to compare the performance of three HIV antibody confirmatory assay kits in confirming early HIV infection.

METHODSFive HIV antibody-positive plasma specimens were ten-fold serially diluted and then detected by ELISA. The above diluted specimens were detected with the following three HIV antibody confirmatory assay kits to analyze their sensitivity, including Wantai-RIBA (Recombinant immunoblot assay, Beijing Wantai Biological Pharmacy, China), MP-WB (HIV Blot 2.2 WB, MP Biomedicals Asia Pacific Pte. Ltd., Singapore) and INNO-LIA (INNO-LIA(TM) HIV I/II Score, Innogenetics N.V., Belgium), respectively. These kits were further used to detect 48 ELISA-reactive specimens from 11 sets of HIV seroconversion specimens (a total of 48 samples) which were previously detected as HIV antibody-positive by ELISA.

RESULTSWhen 5 samples were diluted to 100 fold, Wantai-RIBA still can detect them positive. Among the 48 HIV antibody-positive specimens detected with ELISA, the confirmation positive rate for Wantai-RIBA, MP-WB and INNO-LIA were 97.92% (47/48), 81.25% (39/48) and 91.67% (44/48), respectively. There was statistically significant difference between the confirmatory results of Wantai-RIBA and MP-WB (χ(2) = 6.13, P < 0.05), as well as between those of INNO-LIA and MP-WB (χ(2) = 5.48, P < 0.05); however, there was no statistically significant difference between those of Wantai-RIBA and INNO-LIA (χ(2) = 1.33, P > 0.05). For other six HIV seroconversion panels containing indeterminate specimens, the average seroconversion period of time for Wantai-RIBA, MP-WB and INNO-LIA were 0.7, 13.3 and 3.7 days, respectively.

CONCLUSIONCompared with MP-WB, Wantai-RIBA and INNO-LIA could reduce the window period to confirm early HIV infection.